Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Free Radical Biology & Medicine
|
January 1, 1996
Antioxidant properties of hydroxy-flavones
N Cotelle, J L Bernier, J P Catteau, et al.
The Biochemical Journal
|
July 15, 1988
The role of the gulose-mannose part of bleomycin in activation of iron-molecular oxygen complexes
A Kénani, C Bailly, N Helbecque, et al.
Journal of Inorganic Biochemistry
|
November 1, 1987
Complexation of copper(II) by a peptide hybrid of bleomycin and amsacrine. Circular dichroism and electron spin resonance studies
C Bailly, J P Catteau, N Helbecque, et al.
Journal of Pharmaceutical Sciences
|
April 1, 1989
2,3-bis(2-pyridyl)-5,8-quinoxalinediones with metal chelating properties: synthesis and biological evaluation
S Giorgi-Renault, P Gebel-Servolles, P Helissey, et al.
Bioconjugate Chemistry
|
December 24, 1997
Synthesis, DNA binding, and cleaving properties of an ellipticine-salen.copper conjugate
S Routier, J L Bernier, J P Catteau, et al.
Journal of Inorganic Biochemistry
|
February 15, 1992
The coordination of copper(II) to 1-hydroxy-4-(glycyl-histidyl-lysine)-anthraquinone; a synthetic model of anthraquinone anti-cancer drugs
L D Pettit, J Ueda, E Morier-Teissier, et al.
Bioorganic & Medicinal Chemistry
|
August 1, 1996
Salen-anthraquinone conjugates. Synthesis, DNA-binding and cleaving properties, effects on topoisomerases and cytotoxicity
S Routier, N Cotelle, J P Catteau, et al.
Free Radical Research
|
May 8, 2000
4-Mercaptoimidazoles derived from the naturally occurring antioxidant ovothiols 1. Antioxidant properties
V Zoete, F Bailly, H Vezin, et al.
Biological & Pharmaceutical Bulletin
|
January 6, 2001
Purification of human ceruloplasmin as a by-product of C1-inhibitor
F Kouoh Elombo, M Radosevich, M Poulle, et al.
Anti-Cancer Drug Design
|
June 1, 1989
Synthesis, biological activity and DNA interaction of anilinoacridine and bithiazole peptide derivatives related to the anti-tumor drugs m-AMSA and bleomycin
E Morier-Teissier, C Bailly, J L Bernier, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Free Radical Biology & Medicine
|
January 1, 1996
Antioxidant properties of hydroxy-flavones
N Cotelle, J L Bernier, J P Catteau, et al.
The Biochemical Journal
|
July 15, 1988
The role of the gulose-mannose part of bleomycin in activation of iron-molecular oxygen complexes
A Kénani, C Bailly, N Helbecque, et al.
Journal of Inorganic Biochemistry
|
November 1, 1987
Complexation of copper(II) by a peptide hybrid of bleomycin and amsacrine. Circular dichroism and electron spin resonance studies
C Bailly, J P Catteau, N Helbecque, et al.
Journal of Pharmaceutical Sciences
|
April 1, 1989
2,3-bis(2-pyridyl)-5,8-quinoxalinediones with metal chelating properties: synthesis and biological evaluation
S Giorgi-Renault, P Gebel-Servolles, P Helissey, et al.
Bioconjugate Chemistry
|
December 24, 1997
Synthesis, DNA binding, and cleaving properties of an ellipticine-salen.copper conjugate
S Routier, J L Bernier, J P Catteau, et al.
Journal of Inorganic Biochemistry
|
February 15, 1992
The coordination of copper(II) to 1-hydroxy-4-(glycyl-histidyl-lysine)-anthraquinone; a synthetic model of anthraquinone anti-cancer drugs
L D Pettit, J Ueda, E Morier-Teissier, et al.
Bioorganic & Medicinal Chemistry
|
August 1, 1996
Salen-anthraquinone conjugates. Synthesis, DNA-binding and cleaving properties, effects on topoisomerases and cytotoxicity
S Routier, N Cotelle, J P Catteau, et al.
Free Radical Research
|
May 8, 2000
4-Mercaptoimidazoles derived from the naturally occurring antioxidant ovothiols 1. Antioxidant properties
V Zoete, F Bailly, H Vezin, et al.
Biological & Pharmaceutical Bulletin
|
January 6, 2001
Purification of human ceruloplasmin as a by-product of C1-inhibitor
F Kouoh Elombo, M Radosevich, M Poulle, et al.
Anti-Cancer Drug Design
|
June 1, 1989
Synthesis, biological activity and DNA interaction of anilinoacridine and bithiazole peptide derivatives related to the anti-tumor drugs m-AMSA and bleomycin
E Morier-Teissier, C Bailly, J L Bernier, et al.
Page
of 8